

Immunogenetic Analysis of Variable Regions Encoding AB1 and γ -Type AB2 Antibodies from the NeuGc-Containing Ganglioside Family

ALEXIS PEREZ,¹ JOSEFA LOMBARDEO,¹ CRISTINA MATEO,¹ GERAUDIS MUSTELIER,¹
MAURO ALFONSO,¹ ANA M. VAZQUEZ,¹ and ROLANDO PEREZ¹

ABSTRACT

The variable regions from P3, a murine monoclonal antibody (MAb) against NeuGc-containing gangliosides, and two anti-idiotypic MAbs directed to P3 MAb were cloned and sequenced. Comparisons with previously reported sequences showed that P3 is a germline antibody encoded by genes from the V_H Q52 and V_K 19 families. Analysis of nucleotides at the heavy chain CDR3 (H-CDR3) showed the presence of an extensive 3' N region that contains almost 50% of the nucleotides of this CDR. In addition, amino acid sequence analysis of the H-CDRs of this MAb revealed the presence of three arginines, two of which are present in the H-CDR3, that could be involved in the interaction of P3 MAb with its electronegative epitope on gangliosides. Anti-idiotypic 1E10, which seems to define a "regulatory" idiotope on P3 MAb (it induces Id+ Ab3), represents a germline Ab2 that belongs to the V_H J558 and V_K 10 gene families. By contrary, the anti-idiotypic 3B11 is an extensively mutated antibody that belongs to the V_H 3660 and V_K 4/5 gene families, defining a "private" idiotope on P3 MAb. Even when different V genes contribute to the variable regions of 1E10 and 3B11 MAbs, they share an acidic motif E/D-D-Y/D-Y-D in H-CDR3, suggesting that both Ab2s recognize paratope positive residues on the Ab1. Therefore, complementary electrostatic interactions involving H-CDR3 from both Ab1 and Ab2, might provide a clue to understand the molecular basis for the generation of γ -type anti-idiotypic antibodies to V regions recognizing glycolylated ganglioside antigens.

INTRODUCTION

GANGLIOSIDES are sialic acid-containing glycolipids that are normal components of mammalian tissues. They are considered as attractive targets for cancer immunotherapy in humans due to changes that occur in their expression patterns during oncogenic transformation. Whereas *N*-glycolyl neuraminic acid (NeuGc) is absent in normal human tissues,⁽¹⁾ the expression of NeuGc-containing gangliosides in some human tumors has been demonstrated.⁽²⁻⁴⁾ Murine monoclonal antibody (MAb) P3 (IgM; k), generated by our group in BALB/c mice, reacts specifically with a broad battery of *N*-glycolyl-containing gangliosides, sulfated glycolipids, and with antigens expressed in human breast tumors.⁽⁵⁾ Immunochemical experiments and molecular modeling have led to the delineation of

the epitope recognized by this MAb, which includes the carboxyl and glycolic hydroxyl groups, together with the nitrogen function of sialic acid.⁽⁶⁾ Previous work in syngeneic model has shown the capacity of this MAb to induce an IgG auto-anti-idiotypic response even when injected alone, results that were not obtained when other murine IgM MAbs were used.⁽⁷⁾

Looking for internal image anti-idiotypic MAbs (Ab2), we immunized BALB/c mice with P3 MAb coupled to KLH in the presence of Freund's adjuvant. Different MAbs were selected and cloned for further studies. All these antibodies inhibit the binding of P3 MAb to GM3(NeuGc), and induced anti-anti-idiotypic antibodies (Ab3) in syngeneic animals, but were unable to generate Ab3 with the same specificity of P3 MAb.⁽⁷⁾ These results suggested that these antibodies were not internal image Ab2 and they were classified as γ -type Ab2. These γ -type Ab2s

¹Department of Antibody Engineering, Center of Molecular Immunology, P.O. Box 16040, Havana 11600, Cuba.

could be distinguished by their different abilities to induce Ab3 sharing idiotopes with P3 MAb in syngeneic animals (Id+ Ab3).

In this paper we try to relate those immunochemical properties with the immunogenetic analysis of the primary structures of P3 MAb and two of the anti-P3 Ab2s previously reported: 1E10 Ab2, which was able to induce Id+ Ab3 response in syngeneic model, and 3B11 Ab2, that showed the highest binding affinity for P3 MAb but was unable to induce Id+ Ab3.⁽⁷⁾ We determined the nucleotide sequences of the variable regions of the heavy and light chains (V_H , V_L) of these antibodies by cloning cDNAs derived from the RNA extracted from hybridoma cells. The frequency of complementary charged residues on both Ab1 and Ab2, suggests that electrostatic interactions contribute to the specificity and high affinity of the γ -type idiotypic recognition, in the V-region repertoire recognizing gangliosides.

MATERIALS AND METHODS

Ab1 and Ab2 MAbs

P3 MAb (IgM, κ) (Ab1) was generated by immunization of BALB/c mice with lysosomes containing NeuGc-GM3 and tetanus toxoid, as previously described.⁽⁵⁾ Syngeneic Ab2 MAbs 1E10 (IgG₁, κ) and 3B11 (IgG₁, κ) were obtained from BALB/c mice immunized with purified P3 MAb coupled to KLH (Keyhole Limpet Haemocyanin) in Freund's adjuvant.⁽⁷⁾

Primers

The following primers were used:

- (1) CMIFOR (3' primer for the heavy chain IgM):
5'-GGAAGCTTAAGACATTTGGGAAGGACTGAC-TCTC-3';
- (2) CG1FOR (3' primer for the heavy chain IgG1);
5'-GGAAGCTTAGACAGATGGGG GTGTCGTTTTG-3';
- (3) CK2FOR (3' primer for the kappa light chain):
5'-GGAAGCTTGAAGATG GATACAGTTGGTG-CAGC-3';
- (4) McKAs.XBA (3' primer for the kappa light chain):
5'-GCGTCTAGAAGTGGATGGTGGGAAGATGG-3';
- (5) VH1BACK (5' primer for the heavy chain framework region 1 (FR1)):
5'-AGGT(G/C)(A/C)A(A/G)CTGCAG(G/C)AGTC(A/T)-GG-3';
- (6) VK8BACK (5' primer for the V_{K8} light chain FR1):
5'-C(A/T)GAGAAATTCAGCTGACCCAGTCTC-3';
- (7) VK1BACK (5' primer for the V_{K1} light chain FR1):
5'-GACATTCAGCTGACCCAGTCTCCA-3';
- (8) MLALT4.RV (5' primer for the light chain signal sequence)
5'-GGGGATATCCACCATGAGG(G/T)CCCC(A/T)-(G/A)CTCAG(C/T)T(C/T)C(T/G)GT-3'.

Primers 1-3 contain a *Hind* III restriction site; primers 5-7 contain a *Pst* I restriction site; primer 4 contains a *Xba* I restriction site; primer 8 contains an *Eco* RV restriction site.

cDNA synthesis

Total cellular RNA was extracted by Trizol reagent (Gibco-BRL, Paisley, Scotland). First strand cDNA was synthesized from 5 μ g of total RNA, using a first-strand cDNA synthesis kit (Gibco BRL), essentially as described by the manufacturer. Specific primers complementary to the coding strand of the 5' end of the constant regions (CH1 heavy and kappa light chains) were used. Primers 1 and 2 were used in the VH cDNA synthesis of P3 and Ab2 MAbs, respectively; primer 3 was used in the VL cDNA synthesis of P3 and 3B11 MAbs; primer 4 was used in the VL cDNA synthesis of 1E10 MAb. Before polymerase chain reaction (PCR), samples were heat-treated to inactivate reverse transcriptase.

PCR amplification of V-genes

cDNAs were amplified by PCR as described by Orlandi et al.,⁽⁸⁾ using one unit of Vent DNA polymerase, 200 μ M dNTP and 0.5 μ M of each primer in a final volume of 50 μ L of reaction buffer essentially as described by the manufacturer (New England Biolabs, Inc., Beverly, MA). Primers 1 and 5 were used for the amplification of VH P3. Primers 3 and 6 were used for the amplification of VL P3. Primers 2 and 5 were used for the amplification of VH of Ab2. Primers 3 and 7 were used for the amplification of VL 3B11. Primers 3 and 8 were used for the amplification of VL 1E10.

Each reaction mixture was subjected to 30 cycles of amplification using a thermal minicycler PTC-150 (MJ Research Inc, Watertown, MA). Each cycle consisted of the following steps: 94°C for 1 min (except first cycle: 4 min), 55°C for 1 min and 72°C for 1 min with a final extension of 10 min at 72°C. Amplified variable regions were analyzed on a 1.8% low melting point agarose/Tris acetate-EDTA (TAE) gel and visualized with ethidium bromide. The band of the expected size was excised and purified by phenol extraction and ethanol precipitation.

Cloning and sequencing of PCR products

For cloning, purified products were ligated into the M13mp19 vector (Pharmacia Biotech, Uppsala, Sweden). The amplified cDNAs encoding the heavy chain variable regions of P3 and Ab2 MAbs were digested with *Hind*III and *Pst*I and ligated into the M13mp19 vector, which was previously digested with *Hind* III and *Pst* I. The amplified cDNA encoding the light chain variable regions of P3 and 3B11 were digested with *Hind* III and *Pvu* II and ligated into M13mp19 vector, previously digested with *Hind* III and *Hinc* II. The amplified cDNA encoding the light chain variable region of 1E10 was digested with *Hind* III and *Eco* RV and ligated into M13mp19 vector, previously digested with *Hind* III and *Hinc* II. A standard ligation protocol⁽⁹⁾ was performed using T4 DNA Ligase (Gibco-BRL, Gaithersburg, MD). XL1-Blue cells were transformed and plated for blue-white selection on X-Gal-IPTG plates. White colonies were picked and single strand M13mp19 DNA was purified by phenol extraction after precipitation of phage particles from cultures in liquid media.

Sequencing of the variable regions was performed by the dideoxy method using the T7 sequencing kit (Pharmacia Biotech). The M13 universal primer was used for sequencing. In addition, each variable region was separately amplified,

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25			
VH 1E10	Q	V	Q	L	Q	Q	S	G	A	E	L	V	K	P	G	A	S	V	K	L	S	C	K	A	S			
	CAG	GTT	CAG	CTG	CAG	CAG	TCT	GGA	GCT	GAA	CTG	GTA	AAG	CCT	GGG	GCT	TCA	GTG	AAG	TTG	TCC	TGC	AAG	GCT	TCT			
VH H35-C7	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---			
V _H 102.1	---	---	Q	---	---	P	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---			
	L	Q	X	S	G	P	G	L	V	K	P	S	Q	S	L	S	L	T	C	S	V	T			
VH 3B11	CTG	CAG	NAG	TCN	GGA	CCT	GGC	CTC	GTG	AAA	CCT	TCT	CAG	TCT	CTG	TCT	CTC	ACC	TGC	TCT	GTC	ACT			
	E	V	Q	---	---	E	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---			
VH MRB9	GAT	GTA	CAG	--T	---	G--	--A	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---			
V _H EA7	---	---	---	---	---	---	---	---	---	--G	---	---	---	---	---	---	---	---	---	--C	-N-	---	---	A--	---			
	CDR1																											
	26	27	28	29	30	31	32	33	34	35	35a	35b	36	37	38	39	40	41	42	43	44	45	46	47	48			
VH 1E10	G	Y	T	F	T	S	Y	D	I	N	---	---	W	V	R	Q	R	P	E	Q	G	L	E	W	I			
	GGC	TAC	ACC	TTC	ACA	AGC	TAT	GAT	ATA	AAC	---	---	TGG	GTG	AGG	CAG	AGG	CCT	GAA	CAG	GGA	CTT	GAG	TGG	ATT			
VH H35-C7	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---			
VH102.1	---	---	---	---	---	---	---	---	---	---	---	---	---	---	K	---	---	---	E	---	---	---	---	---	---			
	G	Y	S	I	S	S	G	Y	Y	W	N	---	W	I	R	Q	F	P	G	N	K	L	E	W	M			
VH 3B11	GGC	TAC	TCC	ATC	TCC	AGT	GGT	TAT	TAC	TGG	AAC	---	TGG	ATC	CGG	CAA	TTT	CCA	GGA	AAC	AAA	CTG	GAA	TGG	ATG			
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---			
VH MRB9	---	---	---	---	A--	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---			
V _H EA7	---	---	--A	---	A--	---	-A-	---	A	---	---	---	---	---	---	---	--G	---	---	---	---	---	---	---	---			
	CDR2																											
	49	50	51	52	52a	52b	52c	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70			
VH 1E10	G	W	I	F	P	---	---	G	D	G	S	T	K	Y	N	E	K	F	K	G	K	A	T	L	T			
	GGA	TGG	ATT	TTT	CCT	---	---	GGA	GAT	GGT	AGT	ACT	AAG	TAC	AAT	GAG	AAG	TTC	AAG	GGC	AAG	GCC	ACA	CTG	ACT			
VH H35-C7	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---			
VH102.1	---	---	---	-A-	---	---	---	R	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	T--			
	G	S	I	R	---	---	---	Y	D	G	S	N	D	C	N	P	S	L	K	N	R	I	S	I	T			
VH 3B11	GGC	TCC	ATA	AGG	---	---	---	TAC	GAC	GGT	AGC	AAT	GAC	TGC	AAC	CCA	TCT	CTC	AAA	AAT	CGA	ATC	TCC	ATC	ACT			
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---			
VH MRB9	---	-A-	---	--C	---	---	---	---	--T	---	---	---	A--	-A-	---	---	---	---	---	---	---	---	---	---	---			
V _H EA7	---	-A-	---	--C	---	---	---	---	S	---	---	T	S	Y	---	---	---	---	S	---	---	---	---	---	---			
	---	-A-	---	--C	---	---	---	---	AGT	---	---	-C-	AG-	-A-	---	---	---	---	-G-	---	---	---	---	---	---			
	71	72	73	74	75	76	77	78	79	80	81	82	82a	82b	82c	83	84	85	86	87	88	89	90	91	92			
VH 1E10	T	D	K	S	S	S	T	A	Y	M	Q	L	S	R	L	T	S	E	D	S	A	V	Y	F	C			
	ACA	GAC	AAA	TCC	TCC	AGC	ACA	GCC	TAC	ATG	CAG	CTC	AGC	AGG	CTG	ACA	TCT	GAG	GAC	TCT	GCT	GTC	TAT	TTC	TGT			
VH H35-C7	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---			
VH102.1	V	T	---	---	---	---	---	---	---	---	E	---	H	S	---	---	---	---	---	---	---	---	---	---	---			
	GT-	---	-C-	---	---	---	---	-G	---	---	G--	---	CA-	--C	---	---	---	---	---	---	---	---	---	---	---			
	R	D	T	S	R	N	Q	F	F	L	K	L	N	S	V	T	S	E	D	T	A	T	Y	Y	C			
VH 3B11	CGT	GAC	ACA	TCT	AGG	AAC	CAG	TTT	TTC	CTG	AAG	TTG	AAT	TCT	GTG	ACT	TCT	GAG	GAC	ACA	GCT	ACA	TAT	TAC	TGT			
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---			
VH MRB9	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---			
V _H EA7	--A	---	--C	-A-	---	---	--C	---	---	C--	---	---	---	A--	---	---	A--	---	-G-	--C	---	-C-	---	---	---			
	CDR3																											
	93	94	95	96	97	98	99	100	100a	b	c	d	101	102	103	104	105	106	107	108	109	110	111					
VH 1E10	A	R	E	D	Y	Y	D	N	S	Y	Y	F	D	Y	W	G	Q	G	T	T	L	T	V					
	GCA	AGA	GAA	GAC	TAC	TAT	GAT	AAC	TCC	TAC	TAC	TTT	GAC	TAC	TGG	GGC	CAA	GGC	ACC	ACT	CTC	ACA	GTC					
VH H35-C7	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---					
V102.1	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---					
	A	R	D	D	D	Y	D	W	---	---	---	---	F	A	Y	W	G	Q	G	T	L	V	T	V				
VH 3B11	GCA	AGA	GAT	GAT	TAC	TAC	GAC	TGG	---	---	---	---	TTT	GCT	TAC	TGG	GGC	CAA	GGG	ACT	CTG	GTC	ACT	GTC				
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---				
VH MRB9	---	--T	CTA	C--	ACG	ATG	CC-	---	---	---	---	---	TAC	--C	-A-	GT-	---	---	---	---	---	---	---	---				
V _H EA7	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---				

FIG. 2. Nucleotide and deduced amino acid sequences of the mRNA encoding the heavy chain variable regions of anti-idiotypes 1E10 (VH 1E10) and 3B11 (VH 3B11) compared with the most closely related germline and cDNA sequences (see text). (For details, see legend to Fig. 1. X means unknown amino acid.)

TABLE 1. GENE SEGMENT USAGE IN P3 MAb AND Ab2 ANTIBODIES

<i>MAb</i>	<i>Isotype</i>	<i>V_H</i>	<i>D</i>	<i>J_H</i>	<i>V_κ</i>	<i>J_κ</i>
P3	IgM, κ	Q52 (II)	DSP2	J _H 3	V _κ 19	J _κ 1
1E10	IgG ₁ , κ	J558 (I)	DSP2.2+ DSP2	J _H 2	V _κ 10	J _κ 1
3B11	IgG ₁ , κ	36-60 (III)	DSP2.2	J _H 3	V _κ 4/5	J _κ 5

V_HP3 and V_Hasw1 may be encoded by a germline element other than PJ14. The amino acid Ser₅₆ encoded by V_H P3 is a conserved amino acid that appears in all the germline V_H sequences from Q52 family reported until 1997.⁽¹⁵⁾ Furthermore, divergence nucleotides in codons 45 and 56 of V_H P3 are also present in a high percent (95.6 and 82%, respectively) of the closest 23 sequences (94% or higher identity) extracted from Genbank database with the only exception of V_H asw1. This result strongly suggests that V_H P3 could represent a new undescribed gene from the Q52 family in BALB/c mice.

V_HQ52 gene family has been involved in the antibody response against some gangliosides. Zenita,⁽¹⁶⁾ in a Northern blot analysis of the V_H segments used by a large panel of anti-ganglioside antibodies, found that V_H Q52 genes were preferably used by antibodies directed to gangliosides with sialic acid in $\alpha(2 \rightarrow 6)$ linkage. However, in addition to the present report, the usage of genes from the V_H Q52 family have been previously observed in other autoantibodies directed to $\alpha(2 \rightarrow 3)$ sialic acid-containing gangliosides like GM1⁽¹⁷⁾ and GM2 (G. Mustelier, manuscript in preparation). In BALB/c mice, the V_H Q52 genes are highly represented in the fetal B-cell repertoire, due to the preferential usage of these genes by CD5⁺ B lymphocytes (B-1 cells), the predominant B-cell subpopulation at this period.^(18,19) Furthermore, it is known that this preference for D-proximal gene families like Q52 and 7183 is also ob-

served in adult's B-1 cells.^(19,20) The frequent appearance of V_H genes from this family in anti-ganglioside antibodies might be due to the involvement of B-1 cells in their production.

V_H 1E10 (Fig. 2) is a member of the J558 (V_H I) family, the most J_H-distal group of V_H genes in BALB/c mice. Although it has 93% identity from codons 4 to 94 to V102.1, a germline V_H from the V NP group of genes in the same family,⁽²¹⁾ its V_H segment is almost identical to the one present in H35-C7, a hybridoma generated in BALB/c that produces an antibody to the influenza virus hemagglutinin.⁽²²⁾ There is only one amino acid difference at the position 94 (Arg \rightarrow Asp), that possibly was originated during the recombination process. This strongly suggests that 1E10 and H35-C7 use the same germline V_H gene from J558 gene family, but different to the V102.1 gene, defining most likely a new V_H gene segment.

When compared with germline V_H gene segments, the cDNA sequence of V_H 3B11 showed 89% nucleotide identity from codons 1 to 94 with V_H EA7 (Fig. 2), a member of the 3660 (V_H III) gene family.⁽²³⁾ There are 21 nucleotide positions that differ between both sequences that appear all along the V_H segments. The most homologous sequence to V_H 3B11 is the cDNA sequence from MRB9, a polyreactive murine MAb that binds to purified total histones.⁽²⁴⁾ Both sequences share a 95% homology, having differences in 11 nucleotide positions (codons 1 to 94). According to this analysis V_H 3B11 belongs

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25
VkP3	D	I	V	M	T	Q	S	H	K	F	M	S	T	S	V	G	D	R	V	S	I	T	C	K	A
VkH250-6	GAC	ATG	GTG	ATG	ACC	CAG	TCT	CAC	AAA	TTC	ATG	TCC	ACA	TCA	GTA	GGA	GAC	AGG	GTC	AGC	ATC	ACC	TGC	AAG	GCC

	CDR1																								
	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50
VkP3	S	Q	D	V	S	T	A	V	A	W	Y	Q	Q	K	P	G	Q	S	P	K	L	L	I	Y	S
VkH250-6	AGT	CAG	GAT	GTG	AGT	ACT	GCT	GTA	GCC	TGG	TAT	CAA	CAG	AAA	CCA	GGA	CAA	TCT	CCT	AAA	CTA	CTG	ATT	TAC	TCG

	CDR2																								
	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75
VkP3	A	S	Y	R	Y	T	G	V	P	D	R	F	T	G	S	G	S	G	T	D	F	T	F	T	I
VkH250-6	GCA	TCC	TAC	CGG	TAC	ACT	GGA	GTC	CCT	GAT	CGC	TTC	ACT	GGC	AGT	GGA	TCT	GGG	ACG	GAT	TTC	ACT	TTC	ACC	ATC

	CDR3																								
	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
VkP3	S	S	V	Q	A	E	D	L	A	V	Y	Y	C	Q	Q	H	Y	S	T	P	W	T	F	G	G
VkH250-6	AGC	AGT	GTG	CAG	GCT	GAA	GAC	CTG	GCA	GTT	TAT	TAC	TGT	CAG	CAA	CAT	TAT	AGT	ACT	CCG	TGG	ACG	TTC	GGT	GGA

	101	102	103	104																					
VkP3	G	T	K	L																					
VkH250-6	GGC	ACC	AAG	CTG																					

FIG. 3. Nucleotide and deduced amino acid sequences of the mRNA encoding the light chain variable region of P3 MAb (VkP3) compared with the most closely related cDNA sequence (VkH250-6). (For details, see legend to Fig. 1.)

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25
Vk1E10	D	I	Q	M	T	Q	T	T	S	S	L	S	A	S	L	G	D	R	V	T	I	S	C	R	A
KL2.18	GAT	ATC	CAG	ATG	ACA	CAG	ACT	ACA	TCC	CTG	TCT	GCC	TCT	CTG	GGA	GAC	AGA	GTC	ACC	ATC	AGT	TGC	AGG	GCA	
Vk3B11	L	T	Q	S	P	A	L	M	S	A	S	P	G	E	K	V	T	M	T	C	S	A
38C13	...	GGA	CAA	ATT	GTT	--C	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---
	CDR1																								
	26	27	27a	27b	27c	27d	27e	27f	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44
Vk1E10	S	Q							D	I	S	N	Y	L	N	W	Y	Q	Q	K	P	D	G	T	V
KL2.18	AGT	CAG							GAC	ATT	AGC	AAT	TAT	TTA	AAC	TGG	TAT	CAG	CAG	AAA	CCA	GAT	GGA	ACT	GTT
Vk3B11	S	S							S	V	S	Y	M	Y	W	Y	Q	Q	K	P	R	S	S	P	
38C13	AGC	TCA							AGT	GTA	AGT	TAC	ATG	TAC	TGG	TAC	CAG	CAG	AAG	CCA	AGA	TCC	TCC	CCC	
	CDR2																								
	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69
Vk1E10	K	L	L	I	Y	Y	T	S	R	L	H	S	G	V	P	S	R	F	S	G	S	G	S	G	T
KL2.18	AAA	CTC	CTG	ATC	TAC	TAC	ACA	TCA	AGA	TTA	CAC	TCA	GGA	GTC	CCA	TCA	AGG	TTC	AGT	GGC	AGT	GGG	TCT	GGA	ACA
Vk3B11	K	P	W	I	Y	L	T	S	N	L	A	S	G	V	P	A	R	F	S	G	S	G	S	G	T
38C13	AAA	CCC	TGG	ATT	TAT	CTC	ACA	TCC	AAC	CTG	GCT	TCT	GGA	GTC	CCT	GCT	CGC	TTC	AGT	GGC	AGT	GGG	TCT	GGG	ACC
	CDR3																								
	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94
Vk1E10	D	Y	S	L	T	I	S	N	L	E	Q	E	D	I	A	T	Y	F	C	Q	Q	G	N	T	L
KL2.18	GAT	TAT	TCT	CTC	ACC	ATT	AGC	AAC	CTG	GAG	CAA	GAA	GAT	ATT	GCC	ACT	TAC	TTT	TGC	CAA	CAG	GGT	AAT	ACG	CTT
Vk3B11	S	Y	S	L	T	I	S	S	M	E	A	E	D	V	A	T	Y	Y	C	Q	Q	W	S	S	N
38C13	TCT	TAC	TCT	CTC	ACA	ATC	AGC	AGC	ATG	GAG	GCT	GAA	GAT	GTC	GCC	ACT	TAT	TAC	TGC	CAG	CAG	TGG	AGT	AGT	AAC
	95	95a	95b	96	97	98	99	100	101	102	103	104	105	106	107										
Vk1E10	P			W	T	F	G	G	G	T	K	L	E	S	K										
KL2.18	CCG			TGG	ACG	TTC	GGT	GGA	GGC	ACC	AAG	CTG	GAA	ATC	AAA										
Vk3B11	P			L	T	F	G	A	G	T	K	L	Q	L	K										
38C13	CCG			CTC	ACG	TTC	GGT	GCT	GGG	ACC	AAG	CTG	CAG	CTG	AAA										
		G	L	F			S					E	I												
	--A	GGT	TTA	T--	---	---	--C	T-G	---	--A	---	T--	G-A	A-A	---										

FIG. 4. Nucleotide and deduced amino acid sequences of the mRNA encoding the light chain variable regions of anti-idiotypes 1E10 (Vk1E10) and 3B11 (Vk3B11) compared with the most closely related germline and cDNA sequences (see text). [For details, see legend to Fig. 1.]

to the 3660 (V_H III) family. Therefore, γ -type anti-idiotypic antibodies to the same Ab1 (P3 MAb) can be obtained from different V_H gene families.

Analysis of VL gene usage

The light chain variable region cDNA sequences of the three MAbs presented here are derived from different V_κ gene families (Table 1). The VL sequence of P3 belongs to the V_κ 19 family wand is 100% identical to one of its members, H250-6, an anti-influenza virus hemagglutinin MAb originated from a BALB/c mouse⁽²²⁾ (Fig. 3). This identity involves both the use of the same V_κ gene segment (codons 1–95) and of the same J_κ gene segment (J_κ 1, codons 96–107, Fig. 5A). The fact that the light chain variable region of P3 MAb is fully identical to the one corresponding to H250-6 MAb, suggests that P3 H chain probably contributes more than the L chain to the combining site to gangliosides.

The VL 1E10 sequence is a member of the V_κ 10 family and uses the V-IdCR gene segment. VL 1E10 sequence is identical to that present in KL2.18, KL4C11, and KL4B10 MAbs (M63608, M63617, and M63615, respectively, in Genbank database). This VL sequence is associated with the antibody re-

sponse against *p*-azophenylarsonate in A mice (CAL-20xA/J)F1.⁽²⁵⁾ VL 1E10 is 100% identical to VL KL2.18 in codons 1 to 107, implying the use of the same V_κ and J_κ (J_κ 1) gene segments.

The VL sequence of 3B11 belongs to V_κ -Ox1 superfamily.⁽²⁶⁾ It is 99.3% identical in nucleotides to the VL of 38C13, an antibody with unknown specificity produced by a murine B-cell lymphoma of the same name.⁽²⁷⁾ The V_κ segment sequences (codons 1–95) of both antibodies differ only in two nucleotides that do not lead to amino acid replacements. In VL 3B11, J_κ 5 is used (Fig. 5), and FR4 sequence differs from the sequence of this gene by one nucleotide leading to one amino acid replacement (Glu₁₀₅ → Gln₁₀₅). In 38C13, J_κ 4 is used.

In conclusion, based on the identity of the light chain variable regions either from 1E10 or 3B11 MAbs to previously reported sequences, one might expect a greater contribution of VHs than VLs to the Ab2 binding sites to P3 MAb.

Quantitative and qualitative analysis of somatic hypermutations

Sequence analysis presented above of the heavy and light chain variable regions demonstrated the germline nature of P3




FIG. 5. Possible origins of heavy and light chain CDR3 of P3 (A) and anti-idiotypic MAbs 1E10 and 3B11 (B). P and N nucleotides are represented with asterisks. Dashed lines indicate homology with known D and J genes. The germline sequences of DSP2.2, DSP2.6 and DSP2.7, together with all the germline J sequences, are from Kabat et al.⁽¹⁰⁾ The germline sequences DSP2.10 and DSP2.11 are from the International Immunogenetics Database (IMGT: <http://www.ebi.ac.uk/imgt/>). H-CDR amino acids are represented according to their frequencies in each position in a compilation of murine V_H from Kabat database (<http://immuno.bme.nwu.edu>). (For details, see legend to Fig. 1.)

and 1E10 MAbs. On the other hand, 3B11 MAb showed features of extensive somatic mutations. As a replacement to silent mutation ratio (R/S) greater than 2.9 has been proposed to indicate a positive selection of nucleotide changes that affect amino acid sequence,⁽²⁸⁾ this ratio was calculated for the CDR and framework regions of V_H 3B11. A quantitative and qualitative analysis of R and S mutations in V_H 3B11 showed a pattern which is characteristic for hypermutated antibodies. There is a clear tendency to cluster replacement (and nonconservative) mutations in the H-CDRs, whereas all mutations in the frameworks tend to be silent or conservative. Whereas FR regions of V_H 3B11 showed an R/S ratio of 2 (4/2 < 2.9), this ratio was 4 (4/1 > 2.9) for the CDRs. Furthermore, replacement mutations in FRs involved conservative amino acid changes, with the only exception of Ser₉₄ → Arg₉₄, most likely originated during V_H-D-J_H recombination process. By contrary, all

the replacement mutations that appear in the H-CDRs 1 and 2 involved nonconservative amino acid changes.

Other data supporting the evidence of somatic mutations in V_H 3B11 came from comparisons with the closest homologous sequences reported in Genbank. Nucleotides in eight out of ten putative mutated positions of V_H 3B11 were found exclusively in this sequence and only two nucleotides, those in codons 54 and 88, were found to be shared by most VH sequences (90% and 80% of the sequences with 94% or higher identity, respectively), suggesting their germline origin.

In addition, a replacement mutation in FR4 of VL 3B11, confirms the evidence of somatic mutations given above. However, it is striking to find such a great difference between the levels of mutations in both chains. Previous studies have shown that, in general, somatic mutations in H- and L-chain variable regions tend to occur concurrently.⁽²⁹⁾ Nevertheless, in some re-

ports it is possible to find differences in the levels of mutations between the heavy and light chains.^(30,31) This has been interpreted as an evidence of independent activity of the hypermutation machinery in each chain.⁽³¹⁾

Although 3B11 and 1E10 MAbs were generated in the same fusion experiment and both are able to inhibit P3 MAb binding to gangliosides, immunochemical studies have shown that both Ab2s can be differentiated by their binding affinities to Ab1. 3B11 MAb, the one that showed the higher affinity, probably as a consequence of an affinity maturation process, seems to define a “private” idiotope. In fact, 3B11 was unable to induce in syngeneic model anti-anti-idiotypic antibodies that shared idiotopes with P3 MAb, in contrast to the germline-encoded 1E10 MAb that seems to define a “regulatory” idiotope.⁽⁷⁾

Analysis of junctional regions

Only 7 nucleotides out of 42 that codify the H-CDR3 of P3 MAb belong to a D region (Fig. 5A). Either DSP2.10 or DSP2.11 gene segments used in reading frame 3 could have contributed to this region. N nucleotides constitute almost 50% of the sequence of this H-CDR3, and they appear at both sides of the D segment. In particular, the 3'N region, which is more frequently absent or shorter than 5'N region^(11,36) is unusually extensive in this H-CDR3 with 15 nucleotides. Even when this number is higher than average additions catalyzed by TdT enzyme (4–5),⁽³²⁾ the observed (G+C)/(A+T) ratio (3) is characteristic of the activity of this enzyme.⁽³³⁾ The last five amino acids in H-CDR3 of P3 MAb are codified by P nucleotides⁽¹²⁾ and J_H3.

The D segment of 1E10 has 21 nucleotides and is more likely to be derived from fusion of thirteen nucleotides of DSP2.2 and seven nucleotides from another member of DSP2 family (either DSP2.6, DSP2.7, or DSP2.11, could have contributed). Both minigenes are used in reading frame 1. The H-CDR3 of 1E10 has a five nucleotides long 5'N region, whereas 3'N region is absent.

The D segment of 3B11 can be readily assigned to the DSP2.2 germline gene (Fig. 5B), which also contributed to the D region in 1E10. Nine nucleotides in H-CDR3 of 3B11 belong to this D region, for which reading frame 1 is used. As it happens in H-CDR3 of 1E10, the H-CDR3 of 3B11 lacks 3'N nucleotides. There are 4 nucleotide additions at 5' of the D segment, and D and JH segments overlap two nucleotides at junction.

Analysis of CDR amino acid sequences of P3 MAb

To characterize the residues found in the CDRs of our antibodies, two approaches were used. First, we classified residues in each position in the H-CDRs according to their frequencies of appearance in a compilation of murine VH sequences extracted from Kabat database (<http://immuno.bme.nwu.edu>). These frequencies can be retrieved from web site <http://bioinfo.cim.sld.cu/kabat.html>. In the second approach, we calculated and compared the frequency of certain residues in H- and L-CDRs between our antibodies and a compilation of sequences obtained and processed by Brard⁽³⁴⁾ from Kabat database.⁽¹⁰⁾ The major observation is that several key positions, mainly distributed among the H-chain CDRs, present unusual charged residues.

Previously published studies suggested the leading role of electronegative groups from gangliosides (carboxyl and hydroxyl groups in *N*-glycolyl neuraminic acid) and sulfated glycolipids (SO₃⁻ group) in the binding of P3 MAb to these antigens.⁽⁶⁾ These findings first suggested the existence of complementary positive-charged residues in the CDRs of P3 MAb able to interact with those electronegative determinants. In fact, VH P3 has a slightly higher content of basic (R:3, K:1) than acidic (D:1, E:1) amino acid residues (Fig. 1). Analysis of positional frequencies of residues in H-CDRs reveals that arginine is infrequently found in positions 31(4.8%), 98(4.2%), and 100a(2.8%). The presence of lysine at position 64 (CDR2) does not constitute an unusual feature of P3 MAb because it is observed in 81% of murine VH sequences in Kabat's compilation, and this amino acid could possibly play a structural role.⁽³⁵⁾ The presence of arginines at unusual positions and with higher frequencies than those observed in Kabat's compilation (Table 3), has a great relevance in the comprehension of the interaction of P3 MAb and its ligands. Arginines in H-CDR1 and 3, and L-CDR2 of P3 MAb able to establish ionic interactions as well as hydrogen bonds could be possibly involved in the recognition of these structures.

Another interesting feature of P3 MAb amino acid sequence is its H-CDR3. This region contains a high number of positions with infrequent amino acids (57% of the sequence), given in part by random N nucleotides. In addition, whereas several studies have shown the preferred use of D segments in the reading frame 1, which generates tyrosine-rich sequences,^(36,37) the short D segment used in H-CDR3 P3 is translated in reading frame 3, and codifies two of the infrequent amino acids found at this region. The infrequent amino acid-rich sequence of the H-CDR3 in a germline antibody like P3 MAb, could be possibly related to the ability of this MAb to induce in syngeneic model an IgG anti-idiotypic response in the absence of carrier protein or adjuvant.⁽⁷⁾

Analysis of CDR amino acid sequences of Ab2 MAbs

The major finding obtained from 1E10 and 3B11 sequence analysis was the presence of homologous acidic amino acid-rich sequences in their H-CDR3 regions (Fig. 2), in contrast with the low homology observed in their variable region gene segments. The acidic motif, E/D–D–Y/D–Y–D, is codified by N nucleotides between V_H and D, and also by the first D region nucleotides. Both Ab2 share the DSP2.2 minigene, which codifies the last residues in the motif. This is the only murine D minigene that could contribute with two aspartic residues to the CDR3 sequence. During assembly of the heavy chain variable region, a selected D gene element is usually trimmed by an exonuclease to give rise to a core sequence that represents only part of the initial minigene, and random nucleotides are added to one or both ends of this core sequence. The presence of two codons for aspartic acid in DSP2.2 could therefore increase the probability of at least one codon remaining after mutation. This could explain the appearance of this minigene in both H-CDR3 regions, in view of the importance that acidic residues seem to have in the binding sites of 3B11 and 1E10 MAbs.

As it is shown in Table 2, acidic residues in H-CDR3 of Ab2 antibodies constitute the 22.7%, percentage higher than the av-

TABLE 2. FREQUENCIES OF SELECTED AMINO ACIDS IN KABAT CDRs Ab2^a

	<i>CDR1_H</i>			<i>CDR2_H</i>			<i>CDR3_H</i>		
	<i>Ab2</i>	<i>Kabat</i>	Δ	<i>Ab2</i>	<i>Kabat</i>	Δ	<i>Ab2</i>	<i>Kabat</i>	Δ
R/K	0.0	1.7	-1.7	15.1	10.6	4.5	0.0	5.0	-5.0
D/E	9.1	8.1	1.0	12.1	8.3	3.8	38.1	15.4	22.7
Y	27.3	20.9	6.4	6.1	11.6	-5.5	33.3	23.7	9.6
F/W	9.1	8.4	1.3	9.1	4.6	4.5	14.3	4.5	9.8
Q/N	18.2	7.8	10.4	12.1	12.3	-0.2	4.8	3.6	1.2
S/T	18.2	17.8	0.4	15.1	18.9	-3.8	4.8	13.0	-8.2

	<i>CDR1_L</i>			<i>CDR2_L</i>			<i>CDR3_L</i>		
	<i>Ab2</i>	<i>Kabat</i>	Δ	<i>Ab2</i>	<i>Kabat</i>	Δ	<i>Ab2</i>	<i>Kabat</i>	Δ
R/K	4.3	6.9	-2.6	7.1	14.0	-6.9	0.0	2.7	-2.7
D/E	4.3	4.1	0.2	0.0	7.0	-7.0	0.0	4.5	-4.5
Y	13.0	7.4	5.6	7.1	3.0	3.9	0.0	8.1	-8.1
F/W	0.0	0.8	-0.8	0.0	2.6	-2.6	7.1	7.4	-0.3
Q/N	13.0	12.3	0.7	7.1	9.3	-2.2	42.8	18.8	24
S/T	34.8	36.6	-1.8	42.9	33.4	9.5	21.4	25.0	-3.6

^aAb2 stands for 1E10 and 3B11 MAbs. Data in Kabat were taken from Brard et al.⁽³⁸⁾ Kabat stands for 1450 sequences compiled by Kabat et al.⁽¹⁰⁾ The third column (Δ) corresponds to the difference between the first two columns.

erage representation in Kabat's H-CDR3s, whereas basic residues are slightly under-represented. In addition, acidic residues in this CDR are not usually found in their positions in Kabat's compilation (with the only exception of Asp₁₀₁ in VH 1E10, which is codified by the J_H gene segment). Acidic and basic amino acid residues are found in CDRs 1 and 2 of Ab2 antibodies with levels close to those in Kabat's compilation. However, the presence of unusual acidic residues like Asp₃₁ (CDR1) and Asp₅₈ (CDR2) in VH 1E10 and VH 3B11, respectively, and Asp₅₄, which appears in a shared motif DGS (Fig. 3) is noticeable.

In contrast, the light chain CDRs (L-CDRs) of Ab2 present few unusual features. There are no differences in charged residue levels between these L-CDRs and Kabat's compilation (Table 2), supporting the previous suggestion of the major contribution of the Ab2 heavy chains to the binding site to P3 MAb. The only striking deviation from Kabat's compilation appears in the levels of asparagine and glutamine residues in L-chain CDR3s (24% higher than L-chain CDR3 frequency in Kabat's compilation).

Early studies in the field of antigen-antibody interactions have shown that cationic antigens develop anionic antibody re-

TABLE 3. FREQUENCIES OF SELECTED AMINO ACIDS IN KABAT CDRs P3^a

	<i>CDR1_H</i>			<i>CDR2_H</i>			<i>CDR3_H</i>		
	<i>P3</i>	<i>Kabat</i>	Δ	<i>P3</i>	<i>Kabat</i>	Δ	<i>P3</i>	<i>Kabat</i>	Δ
R/K	20.0	1.7	18.3	6.25	10.6	-4.3	14.3	5.0	9.3
D/E	0.0	8.1	-8.1	6.25	8.3	-2.0	7.1	15.4	-8.3
Y	20.0	20.9	-0.9	6.25	11.6	-5.3	7.1	23.7	-17
F/W	0.0	8.4	-8.4	6.25	4.6	1.7	14.3	4.5	9.8
Q/N	0.0	7.8	-7.8	0.0	12.3	-12	7.1	3.6	3.5
S/T	20.0	17.8	2.2	25.0	18.9	6.1	7.1	13.0	-5.9

	<i>CDR1_L</i>			<i>CDR2_L</i>			<i>CDR3_L</i>		
	<i>P3</i>	<i>Kabat</i>	Δ	<i>P3</i>	<i>Kabat</i>	Δ	<i>P3</i>	<i>Kabat</i>	Δ
R/K	9.1	6.9	2.2	14.3	14.0	0.3	0.0	2.7	-2.7
D/E	9.1	4.1	5.0	0.0	7.0	-7.0	0.0	4.5	-4.5
Y	0.0	7.4	-7.4	28.6	3.0	25.3	14.3	8.1	6.2
F/W	0.0	0.8	-0.8	0.0	2.6	-2.6	0.0	7.4	-7.4
Q/N	9.1	12.3	-3.2	0.0	9.3	-9.3	28.6	18.8	9.6
S/T	27.3	36.6	-9.3	42.9	33.4	9.5	28.6	25.0	3.6

^aP3 stands for P3 MAb. Data in Kabat were taken from Brard et al.⁽³⁸⁾ Kabat stands for 1450 sequences compiled by Kabat et al.⁽¹⁰⁾ The third column (Δ) corresponds to the difference between the first two columns.

sponses, whereas the immunization with anionic antigens induces cationic antibodies.⁽³⁸⁾ Variable region sequences analysis of anti-histones^(34,39) and anti-DNA antibodies,⁽⁴⁰⁾ have strongly supported these initial observations. Therefore, the finding of an acidic motif in H-CDR3 of 1E10 and 3B11 Ab2s, and the general excess in acidic amino acids in their H-CDRs suggest that electrostatic interactions with complementary positive residues in the hypervariable loops of P3 MAb, are important in γ -type Ab2-Ab1 interactions.

Our results prompt us to suggest that H-CDR3 residues from 1E10 and 3B11 Ab2 antibodies bind to residues in the H-CDR3 of P3 MAb. This could seem contradictory in view of the lack of mimicry shown by both Ab2 in syngeneic model.⁽⁷⁾ However, the study of the crystal structure of the complex between the Fv fragments of the anti-lysozyme antibody D1.3 and the anti-D1.3 antibody E5.2 (Ab2 β),⁽⁴¹⁾ has shown that the mimicking is functional and involves similar binding interactions rather than exact topological replicas. This concept is particularly relevant to explain the ability of certain antibodies to mimic gangliosides and other carbohydrate-bearing molecules. There are several plausible explanations to be considered for the failure of our anti-idiotypic antibodies to mimic *N*-glycolyl-containing gangliosides. As Fields pointed out,⁽⁴¹⁾ molecular mimicking depends on several factors like the structure of the antigen, the choice of the antibody (Ab1) and of anti-idiotypic antibody, in addition to other numerous complexities of immune responses. Finally, it could be also the case that even when our Ab2 carried the internal image of these antigens, they could not break the tolerance established against these widespread self-structures in mouse. Interestingly, in cancer patients, where *N*-glycolyl-containing gangliosides are nonself antigens, the immunizations with 1E10 MAb induced a specific response against these antigens (M. Alfonso, manuscript in preparation).

REFERENCES

- Higashi H, Naiki M, Matuo S, and Okouchi K: Antigen of "serum sickness" type of heterophile antibodies in human sera: Identification as ganglioside with *N*-glycolylneuraminic acid. *Biochem Biophys Res Commun* 1977;79:388-395.
- Hirabagashi Y, Kasabura H, Matsumoto M, Higashi H, Kato S, Kasai N, and Naiki M: Specific expression of unusual GM2 ganglioside with Hanganutziu-Deicher antigen activity on human colon cancer. *Jpn J Cancer Res (Gann)* 1987;78:251-260.
- Hirabagashi Y, Higashi H, Kato S, Taniguchi M, and Matsumoto M: Occurrence of tumor associated ganglioside antigens with Hanganutziu-Deicher antigenic activity on human melanomas. *Jpn J Cancer Res (Gann)* 1987;78:614-620.
- Marquina G, Waki U, Fernández LE, Kon K, Carr A, Valiente O, Pérez R, and Ando S: Gangliosides expressed in human breast cancer. *Cancer Res* 1996;56:5165-5170.
- Vázquez AM, Alfonso M, Lanne B, Karlsson KA, Carr A, Barroso O, Fernández LE, Rengifo E, Lanio ME, Alvarez C, Zeuthen J, and Pérez R: Generation of a murine monoclonal antibody specific for *N*-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. *Hybridoma* 1995;14:551-556.
- Moreno E, Lanne B, Vázquez AM, Kawashima I, Tai T, Fernández LE, Karlsson K-A, Ångström J, and Pérez R: Delineation of the epitope recognized by an antibody specific for *N*-glycolylneuraminic acid-containing gangliosides. *Glycobiology* 1998;8:695-705.
- Vázquez AM, Pérez A, Hernández AM, Macías A, Alfonso M,

- Bombino G, and Pérez R: Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. *Hybridoma* 1998;17:527-534.
- Orlandi R, Gussow DH, Jones PT, and Winter G: Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. *Proc Natl Acad Sci U S A* 1989;86:3833-3837.
- Sambrook J, Fritsch EF, and Maniatis T: *Molecular cloning: A laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989.
- Kabat EA, Wu TT, Peery HM, Gottesmann KS, and Foeller C: *Sequences of proteins of immunological interest*. 5th ed. U.S. Department of Health and Human Services, U.S. Government Printing Office, Washington, 1991.
- Bangs LA, Sanz IE, and Teale JM: Comparison of D, J_H and junctional diversity in the fetal, adult, and aged B cell repertoires. *J Immunol* 1991;146:1996-2004.
- Lafaille JJ, DeCloux A, Bonneville M, Takagaki Y, and Tonegawa S: Junctional sequences of T cell receptor $\gamma\delta$ genes: implications for $\gamma\delta$ T cell lineages and for a novel intermediate of V-(D)-J joining. *Cell* 1989;59:859-870.
- Sakano H, Maki R, Kurosawa Y, Roeder W, and Tonegawa S: Two types of somatic recombination are necessary for the generation of complete immunoglobulin heavy-chain genes. *Nature* 1980;286:676-683.
- Monestier M, Losman MJ, Novick KE, and Aris JP: Molecular analysis of Mercury-induced antinucleolar antibodies in H-2^S mice. *J Immunol* 1994;152:667-675.
- Almagro JC, Hernández I, Ramírez MC, and Vargas-Madrado E: The differences between the structural repertoires in germline gene segments of mice and humans: implications for the molecular mechanism of the immune response. *Mol Immunol* 1997;34:1199-1214.
- Zenita K, Hirashima K, Shigeta K, Hiraiwa N, Takada A, Hashimoto K, Fujimoto E, Yago K, and Kannagi R: Northern hybridization analysis of V_H gene expression in murine monoclonal antibodies directed to cancer-associated ganglioside antigens having various sialic acid linkages. *J Immunol* 1990;144:4442-4451.
- Weng NP, Ritter E, Yucel E, Zhang D, Ritter G, and Marcus DMJ: Specificity and structure of murine monoclonal antibodies against GM1 ganglioside. *Neuroimmunol* 1994;55:61-68.
- Jeong HD and Teale JM: Contribution of the CD5+ B cell to D-proximal VH family expression early in ontogeny. *J Immunol* 1990;145:2725-2729.
- Casali P, Kasaian MT, and Haughton G: B-1 (CD5 B) cells. In: *Autoimmunity Physiology and Disease*. Coutinho A, and Kazatchkine MD (Eds.). Wiley-Liss Inc., New York, 1994, p. 57.
- Kantor AB, Merrill CE, Herzenberg LA, and Hillson JL: An unbiased analysis of V(H)-D-J(H) sequences from B-1a, B-1b, and conventional B cells. *J Immunol* 1997;158:1175-1186.
- Blankenstein T, Zobelein G, and Krawinkel U: Analysis of immunoglobulin heavy chain V-region genes belonging to the V NP-gene family. *Nucleic Acid Res* 1984;12:6887-5900.
- Kavaler J, Caton AJ, Staudt LM, Schwartz D, and Gerhard W: A set of closely related antibodies dominates the primary antibody response to the antigenic site CB of the A/PR/8/34 influenza virus hemagglutinin. *J Immunol* 1990;145:2312-2321.
- Robbins PF, and Nisonoff A: Characteristics of two idiotypic subfamilies of murine anti-p-azobenzeneuronate antibodies. *J Immunol* 1987;139:3868-3877.
- Novick KE, Fasy TM, Losman MJ, and Monestier M: Polyreactive IgM antibodies generated from autoimmune mice and selected for histone-binding activity. *Int Immunol* 1992;4:1103-1111.
- Wysocki LJ, Gridley T, Huang S, Grandea AG, and Gefter ML: Single germline VH and V kappa genes encode predominating antibody variable regions elicited in strain A mice by immunization with p-azophenyluronate. *J Exp Med* 1987;166:1-11.

26. Kaartinen M, Pelkonen E, Even J, and Makela O: V genes of the primary antibody response of C57BL/10 mice to the hapten phenylloxazolone. *Eur J Immunol* 1988;18:1095–1100.
27. Roth MS, Weiner GJ, Allen EA, Terry VH, Harnden CE, Boehnke M, Kaminsk MS, and Ginsburg D: Molecular characterization of anti-idiotypic antibody resistant variants of a murine B cell lymphoma. *J Immunol* 1990;145:768–777.
28. Shlomchik MJ, Marshak-Rothstein A, Wolfowicz CB, Rothstein TL, and Weigert MG: The role of clonal selection and somatic mutation in autoimmunity. *Nature* 1987;328:805–811.
29. Milstein C: From the structure of antibodies to the diversification of the immune response. *Scand J Immunol* 1993;37:386–398.
30. Chen J, Borden P, Liao J, and Kabat EA: Variable region cDNA sequences of three mouse monoclonal anti-idiotypic antibodies specific for anti- $\alpha(1 \rightarrow 6)$ dextrans with groove- or cavity-type combining sites. *Mol Immunol* 1992;29:1121–1129.
31. David D, and Zouali M: Variable region light chain genes encoding human antibodies to HIV-1. *Mol Immunol* 1995;32:77–88.
32. Mak TW, and Simard JJJ: B-Lymphocyte genes. In: *Handbook of Immune Response Genes*. Plenum Press, New York 1998, pp. 109–70.
33. Meek K, Hasemann C, Pollock B, Alkan SS, Brait M, Slaoui M, Urbain J, and Capra JD: Structural characterization of anti-idiotypic antibodies: Evidence that Ab2s are derived from the germline differently than Ab2s. *J Exp Med* 1989;169:519–533.
34. Brard F, Petit S, Coquerel G, Gilbert D, Koutouzov S, Pérez G, and Tron F: Modeling of anti-nucleosome immunoglobulin Fv domains: Analysis of electrostatic interactions. *Mol Immunol* 1997; 34:793–807.
35. Padlan EA: Anatomy of the antibody molecule. *Mol Immunol* 1994;31:169–217.
36. Ichihara Y, Hayashida H, Miyazawa S, and Kurosawa Y: Only DFL16, DSP2, and DQ52 gene families exist in mouse immunoglobulin heavy chain diversity gene loci, or which DFL16 and DSP2 originate from the same primordial DH gene. *Eur J Immunol* 1989;19:1849–1854.
37. Gu H, Foster I, and Rajewsky K: Sequence homologies, N sequence insertion and JH gene utilization in VHDJH joining: implications for the joining mechanism and the ontogenetic timing of Lyl B cell and B-CLL progenitor generation. *EMBO J* 1990;9:2133–2140.
38. Sela M, and Mozes E: Dependence of the chemical nature of antibodies on the net electrical charge of antigens. *Proc Natl Acad Sci USA* 1967;55:445.
39. Monestier M, Fasy JM, Losman MJ, Novick KE, and Muller S: Structure and binding properties of monoclonal antibodies to core histones from autoimmune mice. *Mol Immunol* 1993;30: 1069–1075.
40. Eilat D, and Anderson WF: Structure-function correlates of autoantibodies to nucleic acids. Lessons from immunochemical, genetic and structural studies. *Mol Immunol* 1994;31:1377–1390.
41. Fields BA, Goldbaum FA, Ysern X, Poljak RJ, and Mariuzza RA: Molecular basis of antigen mimicry by an anti-idiotope. *Nature* 1995;374:739–742.

Address reprint requests to:

Alexis Pérez

Department of Antibody Engineering

Center of Molecular Immunology

P.O. Box 16040

Havana 11600

Cuba

E-mail: alexis@ict.cim.sld.cu

Received for publication October 23, 2000. Accepted after revisions April 21, 2001.